Department of Urology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
Department of Pathology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey.
World J Urol. 2024 Jul 19;42(1):421. doi: 10.1007/s00345-024-05118-7.
High cord radical orchidectomy (HRCO) is accepted as the standard surgical approach in testicular cancer, however low cord orchidectomy (LCRO) can reduce the morbidity of operation without worsening the oncological outcomes.
We retrospectively re-examined the specimens of men to determine the level of spermatic cord invasion (SCI). Men who had proximal SCI with negative surgical margins after HRCO were assumed to have de-novo residual tumour if LCRO was performed. Others were assumed as oncologically similar. We examined the relation between pre-operative variables and SCI and proximal SCI to determine whether prediction of proximal SCI is possible.
196 patients were included. 22 (11%) had SCI and ten (5%) had proximal SCI. Four patients with proximal SCI had positive surgical margins even after HRCO and didn't require additional local treatment. Six patients were assumed to have de-novo residual tumour if LCRO was performed. All six patients were metastatic and had systemic chemotherapy. High platelet count, tumour size, N stage, S stage and M stage were all significantly related with both SCI and proximal SCI (p < 0.05).
Due to low probability of SCI, we think LCRO can safely be performed to reduce morbidity in Stage 1 patients. Although there is a risk for residual tumour in Stage 2-3 patients, currently there is no data that residual tumour would impair the success of systemic chemotherapy. Therefore we can not assume that these patients would be negatively affected. Pre-operative data can be useful to predict the presence of proximal SCI and select appropriate patients for LCRO.
高位精索根治性睾丸切除术(HRCO)被认为是睾丸癌的标准手术方法,然而低位精索切除术(LCRO)可以降低手术的发病率,而不会恶化肿瘤学结果。
我们回顾性地重新检查了男性的标本,以确定精索侵犯(SCI)的水平。如果 HRCO 后近端 SCI 且切缘阴性,则假定 LCRO 后存在新发残留肿瘤。其他情况被认为具有相似的肿瘤学特征。我们检查了术前变量与 SCI 和近端 SCI 的关系,以确定近端 SCI 是否可以预测。
共纳入 196 例患者。22 例(11%)存在 SCI,10 例(5%)存在近端 SCI。4 例近端 SCI 患者即使 HRCO 后切缘阳性也不需要额外的局部治疗。如果行 LCRO,有 6 例患者被假定为存在新发残留肿瘤。所有 6 例患者均为转移性且接受全身化疗。高血小板计数、肿瘤大小、N 分期、S 分期和 M 分期均与 SCI 和近端 SCI 显著相关(p<0.05)。
由于 SCI 的概率较低,我们认为 LCRO 可安全用于降低 1 期患者的发病率。尽管 2-3 期患者存在残留肿瘤的风险,但目前尚无数据表明残留肿瘤会影响全身化疗的成功。因此,我们不能假设这些患者会受到负面影响。术前数据可用于预测近端 SCI 的存在,并选择适合 LCRO 的患者。